



## **INFORMATION DISCLOSURE CITATION**

**ATTY. DOCKET NO.**

1331-334

**APPLICANT**

VON BORSTEL

(Use several sheets if necessary)

**FILING DATE**

SERIAL NO.

09/763,955

February 28, 200

TC/A.U

February 28, 2001

1623

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

PK	Page, T., et al; "A Syndrome of Megaloblastic Anemia, Immunodeficiency, and Excessive Nucleotide Degradation"; <i>Purine and Pyrimidine Metabolism in Man VII, Part B</i> ; pp. 345-348 (1991).
↓	Page, T., et al; "A Syndrome of Seizures and Pervasive Development Disorder Associated with Excessive Cellular Nucleotidase Activity"; <i>Purine and Pyrimidine Metabolism in Man IX</i> ; pp. 789-792 (1998).
↓	Ferrante, R.J., et al; "Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease"; <i>The Journal of Neuroscience</i> ; 20(12), pp 4389-4397, June 15, 2000.
↓	Du, Y., et al; "Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease"; <i>PNAS</i> , Vol. 98, No. 25; pp. 14469-14674 (December 4, 2001).
PL	Ravina, B.M., et al; "Neuroprotective Agents for Clinical Trials in Parkinson's Disease"; <i>American Academy of Neurology</i> ; 60, pp. 1234-1240 (2003).

**\*Examiner**

### Date Considered

7-27-06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.